CD8A and neoplasm: HLA-A1, HLA-A2, and HLA-B35 positive patients could be tested for antigen-specific CD8+ T cells in the SKILs and peripheral blood against 1, 5, and 2 of the used tumor antigens, respectively, by staining with dextrameric MHC complexes (Supplementary Fig. 2).